The role of biological sciences in understanding the genesis and a new therapeutic approach to Alzheimer's disease;Rola nauk biologicznych w zrozumieniu genezy i nowego podejscia terapeutycznego do choroby Alzheimera

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 65, Issue , 2011, Pages 73-92

  Tȩgowska, Eugenia ^a   Wosińska, Adrianna ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Alzheimer's disease; Free radicals; Insulin; Laser; Methylene blue; Mitochondrial diseases; Olfactory test; Oxidative stress

Indexed keywords

EID: 79958848031     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.933430     Document Type: Review

References (141)

1. Anandatheerthavarada H.K., Devi L.: Amyloid precursor protein and mitochondrial dysfunction in Alzheimer's disease. Neuroscientist, 2007; 13: 626-638. (Pubitemid 350077307)
2. Andrási E., Farkas É., Gawlik D., Rösick U., Brätter P.: Brain iron and zinc contents of German patients with Alzheimer Disease. J. Alzheimer Dis., 2000; 2: 17-26. (Pubitemid 30353514)
3. Aoki C., Siekevitz P.: Ontogenic changes in the cyclic adenosine 3', 5'-monophosphate-stimulatable phosphorylation of cat visual cortex proteins, particularly of microtubule-associated protein 2 (MAP 2): effects of normal and dark rearing and of the exposure to light. J. Neurosci., 1985, 5: 2465-2483. (Pubitemid 15226939)
4. Atamna H., Nguyen A., Schultz C., Boyle K., Newberry J., Kato H., Ames B.N.: Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J., 2008; 22: 703-712. (Pubitemid 351348123)
5. Baloyannis S.J.: Mitochondrial alterations in Alzheimer's disease. J. Alzheimers Dis., 2006; 9: 119-126. (Pubitemid 44088243)
6. Bałkowiec-Iskra E.Z., Kurkowska-Jastrzȩbska I.: Wzajemne oddziaływania układów odpornościowego i dopaminergicznego. Farmakoterapia w Psychiatrii i Neurologii, 2005, 1: 51-59.
7. Beeri R., Andres C., Lev-Lehman E., Timberg R., Huberman T., Shani M., Soreq H.: Transgenic expression of human acetylcholinesterase induces progressive cognitive deterioration in mice. Curr. Biol., 1995; 5: 1063-1071.
8. Bennett D.A., Wilson R.S., Schneider J.A., Evans D.A., Mendes de Leon C.F., Arnold S.E., Barnes L.L., Bienias J.L.: Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology, 2003; 60: 1909-1915. (Pubitemid 36736005)
9. Blass J.P., Gibson G.E.: The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease. Rev. Neurol., 1991; 147: 513-525.
10. Blass J.P., Gibson G.E., Hoyer S.: The role of the metabolic lesion in Alzheimer's disease. J. Alzheimers Dis., 2002; 4: 225-232. (Pubitemid 35006054)
11. Bowling A.C., Beal M.F.: Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci., 1995; 56: 1151-1171.
12. Brodbeck J., Balestra M.E., Saunders A.M., Roses A.D., Mahley R.W., Huang Y.: Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons. Proc. Natl. Acad. Sci. USA, 2008; 105: 1343-1346. (Pubitemid 351397055)
13. Callaway N.L., Riha P.D., Bruchey A.K., Munshi Z., Gonzales-Lima F.: Methylene blue improves brain oxidative metabolism and memory retention in rats. Pharmacol. Biochem. Behav., 2004; 77: 175-181. (Pubitemid 38076994)
14. Cardoso S.M., Proenca M.T., Santos S., Santana I., Oliveira C.R.: Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol. Aging, 2004; 25: 105-110. (Pubitemid 37522198)
15. Cardoso S.M., Santos S., Swerdlow R.H., Oliveira C.R.: Functional mitochondria are required for Aβ-mediated neurotoxicity. FASEB J., 2001; 15: 1439-1441.
16. Cash A.D., Aliev G., Siedlak S.L., Nunomura A., Fujioka H., Zhu X., Raina A.K., Vinters H.V., Tabaton M., Johnson A.B., Paula-Barbosa M., Avila J., Jones P.K., Castellani R.J., Smith M.A., Perry G.: Microtubule reduction in Alzheimer's disease and aging is independent of filament formation. Am. J. Pathol., 2003; 162: 1623-1627. (Pubitemid 36512845)
17. Chandler J.E., Harrison C.M., Canal A.M.: Spermatozoal methylene blue reduction: an indicator of mitochondrial function and its correlation with motility. Theriogenology, 2000; 54: 261-271.
18. Chinery P.F.: The mitochondrion and its disorders. Pract. Neurol., 2003; 3: 100-105.
19. Craft S., Asthana S., Cook D.G., Baker L.D., Cherrier M., Purganan K., Wait C., Petrova A., Latendresse S., Watson G.S., Newcomer J.W., Schellenberg G.D., Krohn A.J.: Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology, 2003; 28: 809-822. (Pubitemid 36695035)
20. Craft S., Asthana S., Newcomer J.W., Wilkinson C.W., Matos I.T., Baker L.D., Cherrier M., Lofgreen C., Latendresse S., Petrova A., Plymate S., Raskind M., Grimwood K., Veith R.C.: Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch. Gen. Psychiatry, 1999; 56: 1135-1140.
21. Craft S., Asthana S., Schellenberg G., Baker L., Cherrier M., Boyt A.A., Martins R.N., Raskind M., Peskind E., Plymate S.: Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann. N.Y. Acad. Sci., 2000; 903: 222-228. (Pubitemid 30251561)
22. Cuajungco M.P., Goldstein L.E., Nunomura A., Smith M.A., Lim J.T., Atwood C.S., Huang X., Farrag Y.W., Perry G., Bush A.I.: Evidence that the β-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of Aβ by zinc. J. Biol. Chem., 2000; 275: 19439-19442. (Pubitemid 30441532)
23. Dahm R.: Alzheimer's discovery. Curr. Biol., 2006; 16: R906-R910. (Pubitemid 44692108)
24. Davies D.C., Brooks J.W., Lewis D.A.: Axonal loss from the olfactory tracts in Alzheimer's disease. Neurobiol. Aging, 1993; 14: 353-357. (Pubitemid 23214702)
25. De Felice F.G., Velasco P.T., Lambert M.P., Viola K., Fernandez S.J., Ferreira S.T., Klein W.L.: Aβ oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem., 2007; 282: 11590-11601. (Pubitemid 47100810)
26. De Felice F.G., Vieira M.N.N., Bomfim T.R., Decker H., Velasco P.T., Lambert M.P., Viola K.L., Zhao W.Q., Ferreira S.T., Klein W.L.: Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Aβ oligomers. Proc. Natl. Acad. Sci. USA, 2009; 106: 1971-1976.
27. de la Monte S.M., Wands J.R.: Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J. Alzheimers Dis., 2006; 9: 167-181. (Pubitemid 44088244)
28. de la Monte S.M., Wands J.R.: Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J. Alzheimers Dis., 2005; 7: 45-61. (Pubitemid 40387184)
29. De Sarno P., Shestopal S.A., King T.D., Zmijewska A., Song L., Jope R.S.: Muscarinic receptor activation protects cells from apoptotic effects of DNA damage, oxidative stress, and mitochondrial inhibition. J. Biol. Chem., 2003; 278: 11086-11093. (Pubitemid 36792660)
30. Delacourte A.: Tauopathies: recent insights into old diseases. Folia Neuropathol., 2005; 43: 244-257. (Pubitemid 43109283)
31. Desmet K.D., Paz D.A., Corry J.J., Eells J.T., Wong-Riley M.T., Henry M.M., Buchmann E.V., Connelly M.P., Dovi J.V., Liang H.L., Henshel D.S., Yeager R.L., Millsap D.S., Lim J., Gould L.J., Das R., Jett M., Hodgson B.D., Margolis D., Whelan H.T.: Clinical and experimental applications of NIR-LED photobiomodulation. Photomed. Laser Surg., 2006; 24: 121-128. (Pubitemid 43837144)
32. Devanand D.P., Michaels-Marston K.S., Liu X., Pelton G.H., Padilla M., Marder K., Bell K., Stern Y., Mayeux R.: Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. Am. J. Psychiatry, 2000; 157: 1399-1405.
33. DiMauro T.M., Attawia M., Lilienfeld S., Holy C.: Intranasal red light probe for treating Alzheimer's disease. Patent no: US 7, 351, 253 B2, date of patent 1 Apr. 2008.
34. Doty R.L.: Clinical studies of olfaction. Chem. Senses, 2005; 30(Suppl.1): i207-i209.
35. Doty R.L., Perl D.P., Steele J.C., Chen K.M., Pierce J.D.Jr., Reyes P., Kurland L.T.: Olfactory dysfunction in three neurodegenerative diseases. Geriatrics, 1991; 46(Suppl.1): 47-51.
36. Doty R.L., Reyes P.F., Gregor T.: Presence of both odor identification and detection deficits in Alzheimer's disease. Brain Res. Bull., 1987; 18: 597-600. (Pubitemid 17121630)
37. Eells J.T., Henry M.M., Summerfelt P., Wong-Riley M.T., Buchmann E.V., Kane M., Whelan N.T., Whelan H.T.: Therapeutic photobiomodulation for methanol-induced retinal toxicity. Proc. Natl. Acad. Sci. USA, 2003; 100: 3439-3444. (Pubitemid 36356602)
38. Ertekin-Taner N., Graff-Radford N., Younkin L.H., Eckman C., Baker M., Adamson J., Ronald J., Blangero J., Hutton M., Younkin S.G.: Linkage of plasma Aβ42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science, 2000; 290: 2303-2304. (Pubitemid 32041571)
39. Esiri M.M., Wilcock G.K.: The olfactory bulbs in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry, 1984; 47: 56-60. (Pubitemid 14154239)
40. Fattal O., Budur K., Vaughan A.J., Franco K.: Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics, 2006; 47: 1-7. (Pubitemid 43017115)
41. Flirski M., Sobów T.: W poszukiwaniu wiarygodnych biochemicznych markerów sporadycznej choroby Alzheimera. Aktualności Neurologiczne, 2004; 3: 121-126.
42. Frank R.A., Gesteland R.C., Bailie J., Rybalsky K., Seiden A., Dulay M.F.: Characterization of the sniff magnitude test. Arch. Otolaryngol. Head Neck Surg., 2006; 132: 532-536. (Pubitemid 43742572)
43. Ga̧siorowska D., Korzeniowska K., Jablecka A.: Homocysteina. Farmacja Współczesna 2008, 1: 169-175.
44. Gonzales-Lima F., Bruchey A.K.: Extinction memory improvement by the metabolic enhancer methylene blue. Learn. Mem., 2004; 11: 633-640. (Pubitemid 39299715)
45. Graves A.B., Bowen J.D., Rajaram L., McCormick W.C., McCurry S.M., Schellenberg G.D., Larson E.B.: Impaired olfaction as a marker for cognitive decline. Interaction with apolipoprotein E ε4 status. Neurology, 1999; 53: 1480-1487. (Pubitemid 29491941)
46. Green R.C., Cupples L.A., Kurz A., Auerbach S., Go R., Sadovnick D., Duara R., Kukull W.A., Chui H., Edeki T., Griffith P.A., Friedland R.P., Bachman D., Farrer L.: Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch. Neurol., 2003; 60: 753-759. (Pubitemid 36569895)
47. Gregoire P.E.: Action of methylene blue on body temperature and metabolism. J. Exp. Med., 1931; 54: 827-845.
48. Hamel E., Nicolakakis N., Aboulkassim T., Ongali B., Tong X.K.: Oxidative stress and cerebrovascular dysfunction in mouse models of Alzheimer's disease. Exp. Physiol., 2008; 93: 116-120. (Pubitemid 350293970)
49. Hameroff S., Penrose R.: Orchestrated reduction of quantum coherence in brain microtubules: a model for consciousness. Mathematics Computers Simulation, 1996; 40: 453-480. (Pubitemid 126412608)
50. Hardy J., Selkoe D.J.: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002; 297: 353-356. (Pubitemid 34790756)
51. Hirai K., Aliev G., Nunomura A., Fujioka H., Russel R.L., Atwood C.S., Johnson A.B., Kress Y., Vinters H.V., Tabaton M., Shimohama S., Cash A.D., Siedlak S.L., Harris P.L., Jones P.K., Petersen R.B., Perry G., Smith M.A.: Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci., 2001; 21: 3017-3023. (Pubitemid 32323483)
52. Hyman B.T., Marzloff K., Arriagada P.V.: The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggest a dynamic balance between amyloid deposition and resolution. J. Neuropathol. Exp. Neurol., 1993; 52: 594-600. (Pubitemid 23335735)
53. Irizarry M.C., McNamara M., Fedorchak K., Hsiao K., Hyman B.T.: APP(Sw) transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 1997; 56: 965-973. (Pubitemid 27386126)
54. Ji Z.S., Miranda R.D., Newhouse Y.M., Weisgraber K.H., Huang Y., Mahley R.W.: Apolipoprotein E4 potentiates amyloid b peptide-induced lysosomal leakage and apoptosis in neuronal cells. J. Biol. Chem., 2002; 277: 21821-21828. (Pubitemid 34952334)
55. Joseph J.A., Shukitt-Hale B., Denisova N.A., Prior R.L., Cao G., Martin A., Taglialatela G., Bickford P.C.: Long-term dietary strawberry, spinach, or vitamin E supplementation retards the onset of age-related neuronal signal-transduction and cognitive behavioral deficits. J. Neurosci., 1998; 18: 8047-8055. (Pubitemid 28441042)
56. Kang J.E., Lim M.M., Bateman R.J., Lee J.J., Smyth L.P., Cirrito J.R., Fujiki N., Nishino S., Holtzman D.M.: Amyloid-β dynamics are regulated by orexin and the sleep-wake cycle. Science, 2009; 326: 1005-1007.
57. Kanki T., Nakayama H., Sasaki N., Takio K., Hamasaki N., Kang D.: Mitochondrial nucleoid and transcription factor A. Ann. N.Y. Acad. Sci., 2004; 1011: 61-68. (Pubitemid 38608392)
58. Keaney J.F. Jr., Puyana J.C., Francis S., Loscalzo J.F., Stamler J.S., Loscalzo J.: Methylene blue reverses endotoxin-induced hypotension. Circ. Res., 1994; 74: 1121-1125. (Pubitemid 24176906)
59. Keil U., Hauptmann S., Bonert A., Scherping I., Eckert A., Müller W.E.: Mitochondrial dysfunction induced by disease relevant AβPP and tau protein mutations. J. Alzheimer Dis. 2006; 9: 139-146. (Pubitemid 44078641)
60. Kim M., Hersh L.B., Leissring M.A., Ingelsson M., Matsui T., Farris W., Lu A., Hyman B.T., Selkoe D.J., Bertram L., Tanzi R.E.: Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. J. Biol. Chem., 2007; 282: 7825-7832. (Pubitemid 47093556)
61. Koelzow H., Gedney J.A., Baumann J., Snook N.J., Bellamy M.C.: The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation. Anesth. Analg., 2002; 94: 824-829. (Pubitemid 34263722)
62. Kontush A.: Amyloid-b: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. Free Radic. Biol. Med., 2001; 31: 1120-1131. (Pubitemid 33000134)
63. Kontush A., Berndt C., Weber W., Akopyan V., Arlt S., Schippling S., Beisiegel U.: Amyloid-β is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic. Biol. Med., 2001; 30: 119-128. (Pubitemid 32008095)
64. Korzcyn A.D., Chapman J.: Apolipoprotein E, dementia and strokes. J. Neurol. Sci., 2003; 206: 3-5. (Pubitemid 35448070)
65. Kovács T., Cairns N.J., Lantos P.L.: Olfactory centres in Alzheimer's disease: olfactory bulb is involved in early Braak's stages. Neuroreport, 2001; 12: 285-288. (Pubitemid 32114366)
66. Kowalski J., Olejniczak J., Bartosz G., Pawlicki L., Gburek J.: Aktywność antyoksydacyjna osocza u osób leczonych fluwastatyna̧ i fenofibratem. Polski Przegla̧d Kardiologiczny, 2003; 5: 185-189. (Pubitemid 36764359)
67. Kwok E.S., Howes D.: Use of methylene blue in sepsis: a systematic review. J. Intensive Care Med., 2006; 21: 359-363. (Pubitemid 44664170)
68. Lampl Y., Zivin J.A., Fisher M., Lew R., Welin L., Dahlof B., Borenstein P., Andersson B., Perez J., Caparo C., Ilic S., Oron U.: Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1). Stroke, 2007; 38: 1843-1849. (Pubitemid 46847257)
69. Lee H.G., Perry G., Moreira P.I., Garrett M.R., Liu Q., Zhu X., Takeda A., Nunomura A., Smith M.A.: Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol. Med., 2005; 11: 164-169.
70. Lee H.G., Zhu X., Castellani R.J., Nunomura A., Perry G., Smith M.A.: Amyloid-β in Alzheimer disease: the null versus the alternate hypotheses. J. Pharmacol. Exp. Ther., 2007; 321: 823-829. (Pubitemid 46762675)
71. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E.: Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science, 2001; 293: 1487-1491. (Pubitemid 32801551)
72. Li C., Yousem D.M., Doty R.L., Kennedy D.W.: Neuroimaging in patients with olfactory dysfunction. Am. J. Roentgenol., 1994; 162: 411-418. (Pubitemid 24065446)
73. Lindsay J., Laurin D., Verreault R., Hébert R., Helliwell B., Hill G.B., McDowell I.: Risk factors for Alzheimer's disease: a prospective analysis from the Canadian study of health and aging. Am. J. Epidemiol., 2002; 156: 445-453. (Pubitemid 34976983)
74. Lovell M.A., Robertson J.D., Teesdale W.J., Campbell J.L., Markesbery W.R.: Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci., 1998; 158: 47-52. (Pubitemid 28277534)
75. Lustbader J.W., Cirilli M., Lin C., Xu H.W., Takuma K., Wang N., Caspersen C., Chen X., Pollak S., Chaney M., Trinchese F., Liu S., Gunn-Moore F., Lue L.F., Walker D.G., Kuppusamy P., Zewier Z.L., Arancio O., Stern D., Yan S.S., Wu H.: ABAD directly links Ab to mitochondrial toxicity in Alzheimer's disease. Science, 2004; 304: 448-452. (Pubitemid 38495942)
76. Maddalena A., Papassotiropoulos A., Müller-Tillmanns B., Jung H.H., Hegi T., Nitsch R.M., Hock C.: Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide42. Arch. Neurol., 2003, 60: 1202-1206. (Pubitemid 37099624)
77. Mahley R.W., Weisgraber K.H., Huang Y.: Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2006; 103: 5644-5651.
78. Mancuso M., Siciliano G., Filosto M., Murri L.: Mitochondrial dysfunction and Alzheimer's disease: new developments. J. Alzheimers Dis., 2006; 9: 111-117. (Pubitemid 44078639)
79. Mandi G., Witte S., Meissner P., Coulibaly B., Mansmann U., Rengelshausen J., Schiek W., Jahn A., Sanon M., Wüst K., Walter-Sack I., Mikus G., Burhenne J., Riedel K.D., Schirmer H., Kouyaté B., Müller O.: Safety of the combination of chloroquine and metylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso. Trop. Med. Int. Health, 2005; 10: 32-38. (Pubitemid 40193683)
80. Manelli A.M., Stine W.B., Van Eldik L.J., LaDu M.J.: ApoE and A β1-42 interactions: effects of isoform and conformation on structure and function. J. Mol. Neurosci., 2004; 23: 235-246.
81. Masters C.L., Beyreuther K.: Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Aβ amyloid pathway. Brain, 2006; 129: 2823-2839. (Pubitemid 44684506)
82. Mayer B., Brunner F., Schmidt K.: Inhibition of nitric oxide synthesis by methylene blue. Biochem. Pharmacol., 1993; 45: 367-374. (Pubitemid 23042635)
83. Meissner P.E., Mandi G., Coulibaly B., Witte S., Tapsoba T., Mansmann U., Rengelshausen J., Schiek W., Jahn A., Walter-Sack I., Mikus G., Burhenne J., Riedel K.D., Schirmer R.H., Kouyaté B., Müller O.: Methylene blue for malaria in Africa, results from a dose-finding study in combination with chloroquine. Malar. J., 2006; 5: 84-90.
84. Mesholam R.I., Moberg P.J., Mahr R.N., Doty R.L.: Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's diseases. Arch. Neurol., 1998; 55: 84-90. (Pubitemid 28139109)
85. Messier C.: Diabetes, Alzheimer's disease and apolipoprotein genotype. Exp Gerontol., 2003; 38: 941-946. (Pubitemid 37040796)
86. Mielke R., Kessler J., Szelies B., Herholz K., Wienhard K., Heiss W.D.: Normal and pathological aging - findings of positron-emission-tomography. J. Neural Transm., 1998; 105: 821-837. (Pubitemid 28539832)
87. Mishra A., Saito K., Barbash S.E., Mishra N., Doty R.L.: Olfactory dysfunction in leprosy. Laryngoscope, 2006; 116: 413-416. (Pubitemid 44318102)
88. Mitchell I.J., Heims H., Neville E.A., Rickards H.: Huntington's disease patients show impaired perception of disgust in the gustatory and olfactory modalities. J. Neuropsychiatry Clin. Neurosci., 2005; 17: 119-121. (Pubitemid 40283779)
89. Mochizuki-Oda N., Kataoka Y., Cui Y., Yamada H., Heya M., Awazu K.: Effects of near-infra-red laser irradiation on adenosine triphosphate and adenosine diphosphate contents of rat brain tissue. Neurosci. Lett., 2002; 323: 207-210. (Pubitemid 34311913)
90. Morgan C.D., Covington J.W., Geisler M.W., Polich J., Murphy C.: Olfactory event-related potentials: older males demonstrate the greatest deficits. Electroencephalogr. Clin. Neurophysiol., 1997; 104: 351-358. (Pubitemid 27297767)
91. Morris M.C., Denis A.E., Bienias J.L., Tangney C.C., Bennett D.A., Wilson R.S., Aggarwal N., Schneider J.: Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol., 2003; 60: 940-946. (Pubitemid 36858352)
92. Munoz D.G., Feldman H.: Causes of Alzheimer's disease. CMAJ, 2000; 162: 65-72. (Pubitemid 30048578)
93. Nawroth J.C., Greer C.A., Chen W.R., Laughlin S.B., Shepherd G.M.: An energy budget for the olfactory glomerulus. J. Neurosci., 2007; 27: 9790-9800. (Pubitemid 47492176)
94. Nowak G., Szewczyk B., Wieronska J.M., Branski P., Palucha A., Pilc A., Sadlik K., Piekoszewski W.: Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res. Bull., 2003; 61: 159-164. (Pubitemid 36794273)
95. Nunomura A., Castellani R.J., Lee H.G., Moreira P.I., Zhu X., Perry G., Smith M.A.: Neuropathology in Alzheimer's disease: awaking from a hundred-year-old dream. Sci. Aging Know. Environ., 2006(8): pe10.
96. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., Smith M.A.: Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol., 2001; 60: 759-767. (Pubitemid 32678256)
97. Ohta S., Ohsawa I.: Dysfunction of mitochondria and oxidative stress in the pathogenesis of Alzheimer's disease: on defects in the cytochrome c oxidase complex and aldehyde detoxification. J. Alzheimers Dis., 2006; 9: 155-166. (Pubitemid 44078643)
98. Pearson R.C., Esiri M.M., Hiorns R.W., Wilcock G.K., Powell T.P.: Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1985; 82: 4531-4534. (Pubitemid 15233154)
99. Pedersen W.A., McMillan P.J., Kulstad J.J., Leverenz J.B., Craft S., Haynatzki G.R.: Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp. Neurol., 2006; 199: 265-273. (Pubitemid 43928978)
100. Perry G., Friedman R., Shaw G., Chau V.: Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc. Natl. Acad. Sci. USA, 1987; 84: 3033-3036. (Pubitemid 17064772)
101. Peters J.M., Hummel T., Kratzsch T., Lötsch J., Skarke C., Frölich L.: Olfactory function in mild cognitive impairment and Alzheimer's disease: An investigation using psychophysical and electrophysiological techniques. Am. J. Psychiatry, 2003; 160: 1995-2002. (Pubitemid 39619637)
102. Planel E., Tatebayashi Y., Miyasaka T., Liu L., Wang L., Herman M., Yu W.H., Luchsinger J.A., Wadzinski B., Duff K.E., Takashima A.: Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J. Neurosci., 2007; 27: 13635-13648. (Pubitemid 350278272)
103. Pratico D., Delanty N.: Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am. J. Med., 2000; 109: 577-585.
104. Pratico D., Uryu K., Leight S., Trojanowski J.Q., Lee V.M.: Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci., 2001; 21: 4183-4187. (Pubitemid 32538543)
105. Price J.L., Davis P.B., Morris J.C., White D.L.: The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol. Aging, 1991; 12: 295-312.
106. Raber J.: Androgens, ApoE, and Alzheimer's disease. Sci. Aging Knowledge Environ., 2004: re2.
107. Rake G.: The rapid invasion of the body through the olfactory mucosa. J. Exp. Med., 1937; 65: 303-315.
108. Reiman E.M., Caselli R.J., Yun L.S., Chen K., Bandy D., Minoshima S., Thibodeau S.N., Osborne D.: Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N. Engl. J. Med., 1996; 334: 752-758. (Pubitemid 26089356)
109. Richey P.L., Siedlak S.L., Smith M.A., Perry G.: Apolipoprotein E interaction with the neurofibrillary tangles and senile plaques in Alzheimer disease: implications for disease pathogenesis. Biochem. Biophys. Res. Commun., 1995; 208: 657-663.
110. Rogaeva E., Premkumar S., Song Y., Sorbi S., Brindle N., Paterson A., Duara R., Levesque G., Yu G., Nishimura M., Ikeda M., O'Toole C., Kawarai T., Jorge R., Vilarino D., Bruni A.C., Farrer L.A., St.George-Hyslop P.H.: Evidence for an Alzheimer disease susceptibility locus on chromosome 12 and for further locus heterogeneity. JAMA, 1998; 280: 614-618. (Pubitemid 28502637)
111. Rojas J.C., Lee J., John J.M., Gonzalez-Lima F.: Neuroprotective effects of near-infrared light in an in vivo model of mitochondrial optic neuropathy. Neurobiol. Dis., 2008; 28: 13511-13521.
112. Salaris S.C., Babbs C.F., Voorhees W.D.3rd: Methylene blue as an inhibitor of superoxide generation by xantine oxidase. A potential new drug for attenuation of ischemia/reperfusion injury. Biochem. Pharmacol., 1991; 42: 499-506.
113. Samudralwar D.L., Diprete C.C., Ni B.F., Ehmann W.D., Markesbery W.R.: Elemental imbalances in the olfactory pathway in Alzheimer's disease. J. Neurol. Sci., 1995; 130: 139-145.
114. Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimaraes A., DeTure M., Ramsden M., McGowan E., Forster C., Yue M., Orne J., Janus C., Mariash A., Kuskowski M., Hyman B., Hutton M., Ashe K.H.: Tau suppression in a neurodegenerative mouse model improves memory function. Science, 2005; 309: 476-481. (Pubitemid 40994688)
115. Sheng J.G., Mrak R.E., Griffin W.S.: Interleukin 1a expression in brain regions in Alzheimer's disease: correlation with neurotic plaque distribution. J. Neuropathol. Exp. Neurol., 1995; 54: 435.
116. Small G.W., Leuchter A.F., Mandelkern M.A., La Rue A., Okonek A., Lufkin R.B., Jarvik L.F., Matsuyama S.S., Bondareff W.: Clinical, neuroimaging, and environmental risk differences in monozygotic female twins appearing discordant for dementia of the Alzheimer type. Arch. Neurol., 1993; 50: 209-219. (Pubitemid 23054806)
117. Small G.W., Mazziotta J.C., Collins M.T., Baxter L.R., Phelps M.E., Mandelkern M.A., Kaplan A., La Rue A., Adamson C.F., Chang L.: Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA, 1995; 273: 942-947.
118. Soininen H., Kosunen O., Helisalmi S., Mannermaa A., Paljärvi L., Talasniemi S., Ryynänen M., Riekkinen P.Sr.: A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein ε4 allele. Neurosci. Lett., 1995; 187: 79-82.
119. Sorbi S., Bird E.D., Blass J.P.: Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann. Neurol., 1983; 13: 72-78. (Pubitemid 13224203)
120. Stiasny-Kolster K., Clever S.C., Mo″ller J.C., Oertel W.H., Mayer G.: Olfactory dysfunction in patients with narcolepsy with and without REM sleep behaviour disorder. Brain, 2007; 130: 442-449. (Pubitemid 46181097)
121. Suzuki H., Park S.J., Tamura M., Ando S.: Effect of the long-term feeding of dietary lipids on the learning ability, fatty acid composition of brain stem phospholipids and synaptic membrane fluidity in adult mice: a comparison of sardine oil diet with palm oil diet. Mech. Ageing Dev., 1998; 101: 119-128. (Pubitemid 28165639)
122. Takeda A., Perry G., Abraham N.G., Dwyer B.E., Kutty R.K., Laitinen J.T., Petersen R.B., Smith M.A.: Overexpression of heme oxygenase in neuronal cells, the possible interaction with Tau. J. Biol. Chem., 2000; 275: 5395-5399. (Pubitemid 30115170)
123. Tourbier I.A., Doty R.L.: Sniff magnitude test: relationship to odor identification, detection, and memory tests in a clinic population. Chem. Senses, 2007; 32: 515-523. (Pubitemid 47261069)
124. Unger J., McNeill T.H., Moxley R.T. III, White M., Moss A., Livingston J.N.: Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neuroscience, 1989; 31: 143-157. (Pubitemid 19209704)
125. Visarius T.M., Stucki J.W., Lauterburg B.H.: Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats. J. Pharmacol. Exp. Ther., 1999; 289: 820-824. (Pubitemid 29191237)
126. Vladimirov Y.A., Gorbatenkova E.A., Paramonov N.V., Azizova O.A.: Photoreactivation of superoxide dismutase by intensive red (laser) light. Free Radic. Biol. Med., 1988; 5: 281-286. (Pubitemid 19024276)
127. Vyhnalek M., Magerova H., Laczoa J., Hort J.: Olfactory discrimination testing does not differentiate between vascular dementia and Alzheimer's disease. J. Neurol. Sci., 2009; 283: 320.
128. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J.: Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 2002; 416: 535-539. (Pubitemid 34288854)
129. Wetter S., Murphy C.: Apolipoprotein E epsi;4 positive individuals demonstrate delayed olfactory event-related potentials. Neurobiol. Aging, 2001; 22: 439-447. (Pubitemid 32510917)
130. Whalley L.J.: Early-onset Alzheimer's disease in Scotland: environmental and familial factors. Br. J. Psychiatry Suppl., 2001, 40: s53-s59. (Pubitemid 32269770)
131. Wischik C.M., Bentham P., Wischik D.J.: Tau aggregation inhibitor (TAI) therapy with Rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimer's Association International Conference on AD. Chicago 2008, Therapeutic Strategies 1: T167.
132. Wischik C.M., Crowther R.A.: Subunit structure of the Alzheimer tangle. Br. Med. Bull., 1986; 42: 51-56. (Pubitemid 16185780)
133. Wischik C.M., Edwards P.C., Lai R.Y., Roth M., Harrington C.R.: Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl. Acad. Sci. USA, 1996; 93: 11213-11218. (Pubitemid 26333144)
134. Wong-Riley M.T., Liang H.L., Eells J.T., Chance B., Henry M.M., Buchmann E., Kane M., Whelan H.T.: Photobiomodulation directly benefits primary neurons functionally inactivated by toxins: role of cytochrome c oxidase. J. Biol. Chem., 2005; 280: 4761-4771. (Pubitemid 40288647)
135. Xu W., Qiu C., Gatz M., Pedersen N.L., Johansson B., Fratiglioni L.: Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes, 2009; 58: 71-77.
136. 4 enhances amyloid b peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc. Natl. Acad. Sci. USA, 2005; 102: 18700-18705. (Pubitemid 43011289)
137. Zahniser N.R., Goens M.B., Hanaway P.J., Vinych J.V.: Characterization and regulation of insulin receptors in rat brain. J. Neurochem., 1984; 42: 1354-1362. (Pubitemid 14137620)
138. Zeviani M., Di Donato S.: Mitochondrial disorders. Brain, 2004; 127: 2153-2172. (Pubitemid 39382225)
139. Zhao W., Chen H., Xu H., Moore E., Meiri N., Quon M.J., Alkon D.L.: Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J. Biol. Chem., 1999; 274: 34893-34902. (Pubitemid 129509536)
140. Zhu X., Perry G., Moreira P.I., Aliev G., Cash A.D., Hirai K., Smith M.A.: Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. J. Alzheimers Dis., 2006; 9: 147-153. (Pubitemid 44078642)
141. Zou K., Gong J.S., Yanagisawa K., Michikawa M.: A novel function of monomeric amyloid b-protein serving as an antioxidant molecule against metal-induced oxidative damage. J. Neurosci., 2002; 22: 4833-4841. (Pubitemid 37465598)